Bayer, adivo to develop therapeutic antibodiesApril 17, 2019Bayer Animal Health and adivo have signed an agreement to develop therapeutic antibodies for companion animals. The collaboration may be good news for veterinary medicine. Although the use of therapeutic antibodies is not widespread, they offer a variety of healing options for diseases that still cannot be treated with current technology. "Today's agreement is another example of how we realize our innovation strategy," says Douglas Hutchens, DVM, PhD, Bayer Animal Health's head of drug …
SPONSORED CONTENTHelp save more lives with this parvovirus innovationOur Canine Parvovirus Monoclonal Antibody offered a 93% real-world survival rate for puppies afflicted with parvovirus.1 Discover the future of parvo treatment today! + Read More